Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Ph 1/2 Study to Evaluate Safety & Tolerability of FMC-242 Alone and in Combination in Adults With Advanced Solid Tumors (ENGAGE)

11 de noviembre de 2026 actualizado por: Frontier Medicines Corporation

A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of FMC-242 as a Single Agent and in Combination in Participants With Advanced Solid Tumors

The goal of this clinical trial is to learn if treatment in adults with select solid tumors with FMC-242 alone and in combinations with other cancer drugs is safe and effective. The main questions it aims to answer are:

Is treatment with FMC-242 alone safe and tolerable and at what dose? Is treatment with FMC-242 combined other cancer drugs safe and tolerable and at what doses?

Participants will need to come to the clinic to have the following:

  • Physical exams to see if there are any side effects
  • Standard lab tests to observe blood counts and other values
  • ECGs to measure heart signals
  • Blood drawn to measure how the drugs are being metabolized
  • Imaging such as CT scans to monitor if the cancer is growing or not

Descripción general del estudio

Descripción detallada

This is a first-in-human, Phase 1/2, open-label, multi-center dose escalation and expansion study to evaluate the safety, tolerability, PK, and anti-tumor activity of FMC-242 monotherapy and in combination in participants with locally advanced or metastatic solid tumors. FMC-242 is in a new class of drugs called PI3Kα:RAS breakers. The combination escalation cohorts may enroll while the monotherapy portion is still determining MTD/recommended dose for expansion (RDE).

This study is being conducted in two phases:

Phase 1 Dose Escalation: to determine the MTD and/or preliminary RP2D(s) and dosing regimen of FMC-242 monotherapy and in combination.

Phase 2 Cohort Expansion: to evaluate the efficacy and safety of FMC-242 at the RP2D(s) as a monotherapy and in combination in disease-specific cohorts.

After consenting to participate, participants will complete screening assessments during a Screening Period. Eligible participants will receive FMC-242 orally, at approximately the same time each day.

Depending on the tumor type, participants in combination cohorts will also receive the addition of another cancer drug administered per the local prescribing information/investigational labeling.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

282

Fase

  • Fase 2
  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Males and females of age ≥ 18 years at the time of signing the informed consent document.
  • No known downstream mutations in the AKT or RAS pathway
  • Measurable disease per RECIST v1.1.
  • Documented disease progression on, or disease recurrence after at least 1 line of standard of care (SoC) systemic treatment, including approved targeted therapy for patients with actionable mutations, or, in the opinion of the Investigator, would not be able to tolerate SoC therapy, or refused SoC therapy.
  • Eastern Cooperative Oncology Group performance status 0-1.
  • Adequate hematological, renal, and hepatic function.
  • In Phase 1 only, must be willing to provide an on treatment tumor biopsy provided it is safe and medically feasible.
  • Women and men of child-bearing potential must agree to use highly effective contraceptive methods.
  • Willing and able to adhere to the study visit schedule and other protocol requirements.
  • Has an archival tissue for retrospective confirmatory testing, unless discussed with the study Medical Monitor.

Exclusion Criteria:

  • Prior use of a PI3Kα:RAS breaker (e.g., BBO-10203, VVD-159642).
  • Prior use of a RAS inhibitor (either pan-RASi or isoform-specific)
  • Received any systemic anti-cancer therapy or investigational therapy within 21 days or 5 half-lives, whichever is shorter, prior to the first dose of study drug.
  • Received radiation within 14 days prior to the first dose of study drug.
  • Clinically significant toxicity resulting from prior cancer therapies that have not returned to baseline or ≤ Grade 1
  • Known, uncontrolled central nervous system (CNS) metastases.
  • History of myocardial infarction or unstable angina within 6 months prior to enrollment, or clinically significant cardiac disease
  • Prior malignancy, requiring treatment or intervention, within the previous 3 years of study drug dosing, except for appropriately treated local malignancies that have been apparently cured, such as basal or squamous cell skin cancer, which are allowed.
  • Pregnant or breastfeeding.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: FMC-242 Monotherapy

FMC-242 alone

PI3Kα:RAS breaker

Experimental: Combination Cohort A

FMC-242 in combination with trastuzumab

PI3Kα:RAS breaker

HER2 targeting agent

Otros nombres:
  • Herceptina
Experimental: Combination Cohort B

FMC-242 in combination with fulvestrant

PI3Kα:RAS breaker

selective estrogen receptor degrader

Otros nombres:
  • Faslodex
Experimental: Combination Cohort C

FMC-242 in combination with a Pan (K)RAS inhibitor

PI3Kα:RAS breaker

Pan (K)RAS inhibitor

Experimental: Combination Cohort D

FMC-242 in combination with FMC-376

PI3Kα:RAS breaker

KRAS G12C inhibitor (experimental)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Phase 1 and Phase 2: Adverse Events
Periodo de tiempo: Approximately 24 months

Number and grade of adverse events (AEs) with FMC-242 alone and in each of the combinations using CTCAE v 6.0

Approximately 24 months
Phase 1 : Dose Limiting Toxicities
Periodo de tiempo: Up to 21 or 28 days

Number of dose limiting toxicities (DLTs) with FMC-242 alone and in each of the combinations

Up to 21 or 28 days
Phase 2: Overall Response Rate
Periodo de tiempo: Approximately 24 months

Assess the overall response rate (ORR) using RECIST 1.1 in participants treated with FMC-242 alone and in each of the combinations

Approximately 24 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Phase 1: Assess anti-tumor activity
Periodo de tiempo: Approximately 24 months

To assess preliminary anti-tumor activity of FMC-242 alone and in combinations using RECIST v1.1

Approximately 24 months
Phase 1: FMC-242 Maximum observed plasma concentration
Periodo de tiempo: 6 weeks

Measure the maximum observed plasma concentration (Cmax) for FMC-242

6 weeks
Phase 1: FMC-242 time to maximum observed plasma concentration
Periodo de tiempo: 6 weeks

Measure time to maximum observed plasma concentration (Tmax) for FMC-242

6 weeks
Phase 1: FMC-242 trough observed concentration
Periodo de tiempo: 6 weeks

Measure trough observed concentration (Cmin) for FMC-242

6 weeks
Phase 1: Area under the concentration-time curve from time zero to time of last quantifiable concentration or in one dosing interval
Periodo de tiempo: 6 weeks

Measure area under the concentration-time curve from time zero to time of last quantifiable concentration or in one dosing interval (AUC0-t, AUCtau) for FMC-242

6 weeks
Phase 1: Terminal half-life
Periodo de tiempo: 6 weeks

Measure the terminal half-life (t1/2) for FMC-242

6 weeks
Phase 1: Apparent clearance
Periodo de tiempo: 6 weeks

Determine apparent the clearance (Cl/F) for FMC-242

6 weeks
Phase 1: Determine the volume of distribution
Periodo de tiempo: 6 weeks

Determine volume of distribution (Vd/F) for FMC-242

6 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Aaron (Ron) Weitzman, MD, Frontier Medicines

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de diciembre de 2026

Finalización primaria (Estimado)

1 de enero de 2029

Finalización del estudio (Estimado)

1 de enero de 2030

Fechas de registro del estudio

Enviado por primera vez

11 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Publicado por primera vez (Actual)

18 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Aggregate study data will be shared at the end of the study.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir